Fennec Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026, with the U.S. Securities and Exchange Commission on August 13, 2026, reporting net income for both the second quarter and the first half of the year.

Key Highlights

  • PEDMARK net product sales: $17,164 thousand for Q2 2026, compared to $9,652 thousand for Q2 2025, according to the filing.
  • Total revenue: $17,874 thousand for Q2 2026 and $32,982 thousand for the six months ended June 30, 2026, as reported.
  • Net income: $1,973 thousand for Q2 2026, versus a net loss of $3,152 thousand in Q2 2025; net income of $2,174 thousand for the six-month period ended June 30, 2026, versus a net loss of $4,317 thousand for the same period in 2025.
  • Cash and cash equivalents: $41,249 thousand as of June 30, 2026, up from $36,788 thousand at December 31, 2025.
  • Total stockholders' equity: $42,442 thousand at June 30, 2026, compared to $35,472 thousand at December 31, 2025.
  • Common shares outstanding: 35,067,159 as of August 11, 2026, per the filing's cover page.
  • Accumulated deficit: $(227,248) thousand at June 30, 2026, reduced from $(229,422) thousand at December 31, 2025.

Fennec Pharmaceuticals Q2 2026 Financial Results: Revenue Growth and Return to Profitability

Fennec Pharmaceuticals Inc. (NASDAQ:FENC), a smaller reporting company incorporated in British Columbia, Canada, and headquartered in Research Triangle Park, North Carolina, disclosed its unaudited condensed consolidated financial results for the three and six months ended June 30, 2026. According to the filing, PEDMARK net product sales for Q2 2026 reached $17,164 thousand, up from $9,652 thousand in Q2 2025. The company also reported other revenue of $710 thousand in Q2 2026, with no comparable amount in Q2 2025, bringing total Q2 2026 revenue to $17,874 thousand.

The filing reported income from operations of $1,737 thousand for Q2 2026, compared to a loss from operations of $2,732 thousand in Q2 2025. Total operating expenses for Q2 2026 were $16,137 thousand, including selling and marketing expenses of $10,659 thousand and general and administrative expenses of $4,639 thousand. For the six months ended June 30, 2026, total revenue was $32,982 thousand versus $18,403 thousand for the same period in 2025, and the company reported net income of $2,174 thousand compared to a net loss of $4,317 thousand in the prior-year period.

On the balance sheet, total assets stood at $75,753 thousand as of June 30, 2026, up from $70,551 thousand at December 31, 2025. Total liabilities declined to $33,311 thousand from $35,079 thousand over the same period, primarily reflecting a reduction in contract liabilities. The diluted net income per common share for Q2 2026 was $0.05, and for the six-month period was $0.06, based on weighted-average diluted shares of 36,430 thousand and 37,410 thousand, respectively, as stated in the filing.

What Was Disclosed

The filing covers Fennec Pharmaceuticals' unaudited financial statements for the quarter and six months ended June 30, 2026, showing growth in PEDMARK product sales, a return to net income, increased cash balances, and a reduction in the accumulated deficit compared to December 31, 2025.